This is an Asian multi-regional clinical trial (MRCT) in which ATG-008 will be administered
orally to hepatitis B positive (HBV+) HCC subjects who have received at least one prior line
of systemic therapy. It is designed as an open-label phase 2 trial evaluating the
pharmacokinetics (PK), safety, tolerability and efficacy of oral ATG-008 administered daily
until the radiologic disease progression (according to RECIST 1.1) or intolerable toxicity.